See more : Prozone Realty Limited (PROZONER.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Biotest Aktiengesellschaft (BIO1.F) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biotest Aktiengesellschaft, a leading company in the industry within the sector.
- EJF Acquisition Corp. (EJFA) Income Statement Analysis – Financial Results
- Conafi S.p.A. (CNF.MI) Income Statement Analysis – Financial Results
- TradeUP Acquisition Corp. (UPTD) Income Statement Analysis – Financial Results
- Shanghai Foreign Service Holding Group CO.,Ltd. (600662.SS) Income Statement Analysis – Financial Results
- Brederode SA (BREB.BR) Income Statement Analysis – Financial Results
Biotest Aktiengesellschaft (BIO1.F)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.biotest.com
About Biotest Aktiengesellschaft
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 552.63M | 586.84M | 591.50M | 470.11M | 458.59M | 453.63M | 429.43M | 580.61M | 704.47M | 689.66M | 580.13M |
| Cost of Revenue | 418.89M | 494.99M | 432.57M | 325.63M | 304.16M | 305.46M | 251.13M | 353.73M | 432.73M | 403.77M | 336.61M |
| Gross Profit | 133.74M | 91.85M | 158.93M | 144.48M | 154.43M | 148.17M | 178.30M | 226.88M | 271.74M | 285.89M | 243.52M |
| Gross Profit Ratio | 24.20% | 15.65% | 26.87% | 30.73% | 33.67% | 32.66% | 41.52% | 39.08% | 38.57% | 41.45% | 41.98% |
| Research & Development | 54.07M | 59.53M | 68.17M | 59.90M | 55.56M | 66.47M | 50.84M | 85.26M | 81.34M | 88.96M | 67.77M |
| General & Administrative | 33.94M | 34.26M | 34.45M | 35.11M | 36.20M | 54.23M | 34.00M | 35.84M | 38.25M | 42.14M | 36.79M |
| Selling & Marketing | 52.47M | 58.16M | 61.32M | 55.64M | 59.11M | 64.43M | 56.63M | 64.19M | 89.81M | 82.77M | 75.29M |
| SG&A | 87.70M | 93.33M | 97.12M | 92.54M | 97.03M | 120.34M | 92.41M | 101.44M | 130.48M | 127.38M | 115.10M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 147.87M | 149.33M | 181.04M | 137.07M | 154.31M | 170.49M | 142.30M | 181.92M | 203.11M | 214.69M | 191.05M |
| Cost & Expenses | 566.76M | 644.32M | 613.61M | 462.70M | 458.47M | 475.94M | 393.43M | 535.65M | 635.84M | 618.47M | 527.66M |
| Interest Income | 18.95M | 13.89M | 14.54M | 8.86M | 6.99M | 8.88M | 10.74M | 7.17M | 11.86M | 5.37M | 4.35M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 32.77M | 29.71M | 30.42M | 27.59M | 28.18M | 26.75M | 24.10M | 20.85M | 39.34M | 43.79M | 38.76M |
| EBITDA | 11.14M | -28.23M | 21.13M | 12.79M | 29.79M | -14.40M | 58.73M | 59.63M | 100.22M | 113.06M | 94.80M |
| EBITDA Ratio | 2.02% | -4.81% | 3.57% | 2.72% | 6.50% | -3.17% | 13.68% | 10.27% | 14.23% | 16.39% | 16.34% |
| Operating Income | -21.63M | -57.93M | -9.28M | -14.81M | 1.60M | -41.15M | 34.63M | 38.77M | 60.88M | 69.27M | 56.04M |
| Operating Income Ratio | -3.91% | -9.87% | -1.57% | -3.15% | 0.35% | -9.07% | 8.06% | 6.68% | 8.64% | 10.04% | 9.66% |
| Total Other Income/Expenses | -11.46M | -13.43M | -27.36M | 13.35M | -8.48M | 9.96M | -9.37M | -977.46K | -4.12M | -3.44M | -7.91M |
| Income Before Tax | -33.09M | -71.36M | -36.65M | -1.46M | -6.87M | -31.19M | 25.26M | 37.80M | 56.77M | 65.83M | 48.12M |
| Income Before Tax Ratio | -5.99% | -12.16% | -6.20% | -0.31% | -1.50% | -6.88% | 5.88% | 6.51% | 8.06% | 9.54% | 8.30% |
| Income Tax Expense | 856.62K | 796.72K | 1.71M | 3.81M | 7.90M | 11.52M | 18.84M | 8.47M | 33.53M | 21.76M | 17.67M |
| Net Income | -33.94M | -72.16M | -38.36M | -5.72M | -14.78M | -19.68M | 6.32M | 29.32M | 23.24M | 44.07M | 30.46M |
| Net Income Ratio | -6.14% | -12.30% | -6.48% | -1.22% | -3.22% | -4.34% | 1.47% | 5.05% | 3.30% | 6.39% | 5.25% |
| EPS | -0.86 | -1.82 | -0.97 | -0.14 | -0.37 | -0.50 | 0.16 | 0.74 | 0.59 | 1.18 | 0.87 |
| EPS Diluted | -0.86 | -1.82 | -0.97 | -0.14 | -0.37 | -0.50 | 0.16 | 0.74 | 0.59 | 1.18 | 0.87 |
| Weighted Avg Shares Out | 39.57M | 39.57M | 39.57M | 39.57M | 39.57M | 39.57M | 39.57M | 39.57M | 39.57M | 37.40M | 35.19M |
| Weighted Avg Shares Out (Dil) | 39.57M | 39.57M | 39.57M | 39.57M | 39.57M | 39.57M | 39.57M | 39.57M | 39.57M | 37.40M | 35.19M |
Source: https://incomestatements.info
Category: Stock Reports